🔗 https://ow.ly/pyBb5107cxv
🔗 https://ow.ly/pyBb5107cxv
🔗 https://ow.ly/g24z50ZXUFi
#ESMOGuidelines Pr Michel Ducreux
🔗 https://ow.ly/g24z50ZXUFi
#ESMOGuidelines Pr Michel Ducreux
🔗 https://ow.ly/2Q5R50ZRjP7
🔗 https://ow.ly/2Q5R50ZRjP7
🔗 https://ow.ly/LgJK50ZQrWC
#ESMOGuidelines
🔗 https://ow.ly/LgJK50ZQrWC
#ESMOGuidelines
@myesmo.bsky.social #EHAGuidelines #ESMOGuidelines
@myesmo.bsky.social #EHAGuidelines #ESMOGuidelines
@myesmo.bsky.social
oncodaily.com/blog/esmo-gu...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ESMO #ESMOGuidelines #BreastCancer #mBC
@myesmo.bsky.social
oncodaily.com/blog/esmo-gu...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ESMO #ESMOGuidelines #BreastCancer #mBC
The most updated #ESMOguidelines on cutaneous melanoma, now out in #AnnOncol. Great to see #TheChristie colleagues @beckilee.bsky.social & Paul Lorigan as co-authors in this panel of esteemed experts 🌍.
🔗 Available #OpenAccess: www.annalsofoncology.org/article/S092...
The most updated #ESMOguidelines on cutaneous melanoma, now out in #AnnOncol. Great to see #TheChristie colleagues @beckilee.bsky.social & Paul Lorigan as co-authors in this panel of esteemed experts 🌍.
🔗 Available #OpenAccess: www.annalsofoncology.org/article/S092...
🔗 https://ow.ly/gz9450ZzOgx
#ESMOGuidelines #PancreaticCancer #CancerResearch #Oncology
Pr Michel Ducreux
🔗 https://ow.ly/gz9450ZzOgx
#ESMOGuidelines #PancreaticCancer #CancerResearch #Oncology
Pr Michel Ducreux
👉 Register now: https://ow.ly/QTag50ZjV0V
#ESMOWebinars #ESMOOnAir
👉 Register now: https://ow.ly/QTag50ZjV0V
#ESMOWebinars #ESMOOnAir
Join the #ESMOGuidelines Webinar for real-world case insights on immunotherapy, treatment sequencing and clinical decisions.
🎓 Earn 1 ESMO-MORA point
👉 https://ow.ly/6n9F50ZeuZo
#ESMOWebinars #ESMOOnAir
Join the #ESMOGuidelines Webinar for real-world case insights on immunotherapy, treatment sequencing and clinical decisions.
🎓 Earn 1 ESMO-MORA point
👉 https://ow.ly/6n9F50ZeuZo
#ESMOWebinars #ESMOOnAir
🔗 https://ow.ly/7ini50Z9jG3
#ClinicalPracticeGuideline #ESMOGuidelines
🔗 https://ow.ly/7ini50Z9jG3
#ClinicalPracticeGuideline #ESMOGuidelines
🔗 https://ow.ly/8Tt450Z5sXY
🔗 https://ow.ly/8Tt450Z5sXY
🎓 Live Q&A with guideline experts
⭐ 1 ESMO‑MORA Cat. 1 point
🔗 Register now: https://ow.ly/seQS50Z257Q
#ESMOWebinars #ESMOOnAir
🎓 Live Q&A with guideline experts
⭐ 1 ESMO‑MORA Cat. 1 point
🔗 Register now: https://ow.ly/seQS50Z257Q
#ESMOWebinars #ESMOOnAir
🎓 Earn 1 ESMO‑MORA point (live attendance)
💬 Live Q&A with Guideline authors
🆓 Open with a free ESMO account
🔗 Register: https://ow.ly/pNqO50YQULE
#ESMOWebinars #ESMOOnAir
🎓 Earn 1 ESMO‑MORA point (live attendance)
💬 Live Q&A with Guideline authors
🆓 Open with a free ESMO account
🔗 Register: https://ow.ly/pNqO50YQULE
#ESMOWebinars #ESMOOnAir
🔗 https://ow.ly/YI1i50YI3Jh
#ESMOGuidelines #Oncology Pr Michel Ducreux
🔗 https://ow.ly/YI1i50YI3Jh
#ESMOGuidelines #Oncology Pr Michel Ducreux
✨Percutaneous hepatic perfusion & tebentafusp: metastatic disease Tx options
✨Key algorithms & recommendations reflecting latest clinical data
🔗 https://ow.ly/u7GU50YC8RR
#Melanoma #Oncology #ESMOGuidelines
✨Percutaneous hepatic perfusion & tebentafusp: metastatic disease Tx options
✨Key algorithms & recommendations reflecting latest clinical data
🔗 https://ow.ly/u7GU50YC8RR
#Melanoma #Oncology #ESMOGuidelines
🎙 Live Q&A with expert faculty
🎓 Earn 1 ESMO-MORA Cat. 1 point
🆓 Open to all with an ESMO account
🔗 Join us: https://ow.ly/SU2g50YlJnP
#ESMOOnAir #ESMOWebinars
🎙 Live Q&A with expert faculty
🎓 Earn 1 ESMO-MORA Cat. 1 point
🆓 Open to all with an ESMO account
🔗 Join us: https://ow.ly/SU2g50YlJnP
#ESMOOnAir #ESMOWebinars
✅ Substantial advances in castration-sensitive & -resistant prostate cancer
✅ Updated algorithms & recommendations reflecting latest clinical data
#ESMOGuidelines Christopher Sweeney
🔗 https://ow.ly/E4ov50Yc8e2
✅ Substantial advances in castration-sensitive & -resistant prostate cancer
✅ Updated algorithms & recommendations reflecting latest clinical data
#ESMOGuidelines Christopher Sweeney
🔗 https://ow.ly/E4ov50Yc8e2
- Rucaparib: 1st-line PARPi maintenance option
- MIRV: for recurrent FRα-high #OvarianCancer after 1-3 prior therapies & PFI <6 months
🔗 https://ow.ly/J06u50Y4HT8
#GYNOnc #Oncology #ESMOGuidelines
- Rucaparib: 1st-line PARPi maintenance option
- MIRV: for recurrent FRα-high #OvarianCancer after 1-3 prior therapies & PFI <6 months
🔗 https://ow.ly/J06u50Y4HT8
#GYNOnc #Oncology #ESMOGuidelines
👥Selected resected patients to be informed & encouraged to participate #Oncology #ESMOGuidelines
🔗 https://ow.ly/lJY850Y49fR
👥Selected resected patients to be informed & encouraged to participate #Oncology #ESMOGuidelines
🔗 https://ow.ly/lJY850Y49fR
Open to all ESMO account holders.
🔗Register here: https://ow.ly/kE7S50Y1Ljw
#ESMOWebinar #ESMOOnAir #CancerGuidelines
Open to all ESMO account holders.
🔗Register here: https://ow.ly/kE7S50Y1Ljw
#ESMOWebinar #ESMOOnAir #CancerGuidelines
✅New imaging modalities: Improved diagnosis, staging & risk stratification
✅Updated algorithms: less over-Tx & fewer side-effects
#Oncology #UroOncology #CancerCare #ESMOGuidelines
🔗 https://ow.ly/jwA650XLs1q
✅New imaging modalities: Improved diagnosis, staging & risk stratification
✅Updated algorithms: less over-Tx & fewer side-effects
#Oncology #UroOncology #CancerCare #ESMOGuidelines
🔗 https://ow.ly/jwA650XLs1q
🔗 Free with your ESMO account: https://ow.ly/RN1E50XAug9
#ESMOWebinars #ESMOOnAir
🔗 Free with your ESMO account: https://ow.ly/RN1E50XAug9
#ESMOWebinars #ESMOOnAir
🔗 Free with your ESMO account: https://ow.ly/xaKa50XuGaW
🔗 Free with your ESMO account: https://ow.ly/xaKa50XuGaW
Session I: HCC & melanoma
📅 19 Oct | 10:15–11:45 | Hall 7.1c
Session II: Lymphomas & early-stage NSCLC
📅 19 Oct | 14:45–16:15 | Hall 7.1c
🔗 buff.ly/h4FL2cU
Session I: HCC & melanoma
📅 19 Oct | 10:15–11:45 | Hall 7.1c
Session II: Lymphomas & early-stage NSCLC
📅 19 Oct | 14:45–16:15 | Hall 7.1c
🔗 buff.ly/h4FL2cU